Image source: Shutterstock

Highlights

  • Orthocell requests trading halt pending U.S. FDA decision on Remplir product approval.

  • FDA clearance would enable entry into the US$1.6 billion U.S. peripheral nerve repair market.

  • Shares have surged over 260% in the past year, outperforming the broader healthcare index.

Orthocell Ltd (ASX:OCC), the Australian regenerative medicine company, has placed its shares into a trading halt as it awaits a pivotal decision from the U.S. Food and Drug Administration (FDA) regarding regulatory clearance for its flagship Remplir nerve repair product.

The company, which specialises in bone and soft tissue regeneration, is seeking FDA 510(k) clearance to begin commercial distribution of Remplir in the U.S.—a move that could unlock access to a high-value market worth an estimated US$1.6 billion.

In a formal statement to the ASX, Orthocell said the trading halt was requested "pending an announcement by the Company regarding the results of the US FDA 510(k) clearance application." The halt will remain in place until Monday, 7 April 2025, or until the company makes the announcement, whichever comes first.

Remplir is designed to aid in peripheral nerve reconstruction, an area of growing clinical demand, particularly in orthopaedic, trauma, and reconstructive surgery. The product has already been used in various international markets and clinical settings, but FDA clearance represents a major milestone—not only opening the door to the U.S. healthcare system but also affirming the product’s safety and efficacy by one of the world’s most stringent regulatory bodies.

Orthocell previously announced in February that it was targeting late March or early April 2025 for the outcome of its FDA application. If successful, the clearance will give the company immediate commercial access to a lucrative and competitive market.

The company’s stock has been a standout performer on the ASX over the past year, with shares gaining more than 260%—a sharp contrast to the broader S&P/ASX 200 Health Care Index (ASX:XHJ), which is down 3% over the same period. On Thursday, before the trading halt was enacted, Orthocell shares were priced at AU$1.47.

With the trading halt now in effect and anticipation building, all eyes are on Monday as investors await the company’s next move